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                                                  INTRODUCTION 
 
                    In higher animals and humans the serum uric acid is an end product of   
purine metabolism, excreted mainly through kidneys. Increased serum uric acid 
levels was thought to be the main reason for arthritis due to crystal deposition in 
joints, renal stones and other vascular events. 
                  More recently, increased levels of serum uric acid levels also involved in 
the future development of hypertension, cardiovascular disease, kidney disease and 
metabolic syndrome 
                Although increased serum uric acid levels are involved in the development 
of many diseases the following mechanisms included as a cause, they are 
dysfunction of endothelium, resistance to insulin, systemic inflammation and 
oxidative stress. 
               Several biological studies shown that increased serum uric acid level have 
been found to correlate directly with the level of tissue injury .Compared to the 
serum levels of uric acid, tissue levels of uric acid has better prediction of tissue 
injury. So serum uric acid may be considered as an indicator of tissue injury 
             Recent studies on serum uric acid have shown an increased serum uric acid 
levels associated with the development of steatosis of liver in the patients who had 
Non-Alcoholic fatty Liver Disease (NAFLD) after adjustment for various features 
of metabolic syndrome. It is proposed that the role of increased uric acid levels in the 
pathogenesis of liver disease thought to be due to its pro-inflammatory effects, for             
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example, increased levels of uric acid is considered as an important marker in the 
pathogenesis of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steato 
hepatitis (NASH). 
                Addition to this, hyperuricemia involved in the progressive development of 
hepatitis C virus related disease and liver diseases due to excessive consumption of 
alcohol. This strongly suggests that increased uric acid levels, strongly reflects and 
even causes an increased oxidative stress, resistance to insulin and inflammation in 
the systemic circulation. This become one of the main risk factors for future 
development of cirrhosis of liver or hepatic inflammation due to necrosis both in 
alcoholic and non-alcoholic 
               Oxidative stress in liver mainly caused by the mitochondrial dysfunction, 
and also by proinflammatory cytokines like tumor necrosis factor alpha (TNF) are 
thought to play a very important role in the progression of liver cell damage in cases 
of nonalcoholic fatty liver disease 
                NAFLD not only directly leads to the development of liver failure and 
hepatocellular carcinoma, but also is involved in the future development of type 2 
diabetes and cardiovascular diseases due to atherosclerosis. NAFLD is complex 
disease and nowadays it is challenging for the human health. 
               In chronic liver disease due to various causes uric acid levels are found to 
be increased .Most of the people with nonalcoholic fatty liver disease, the increased 
uric acid levels are implicated as an important etiological risk factor. Also increased 
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uric acid level has a known effect on alcohol metabolism, hyperuricemia also be 
found in patients with alcoholic liver disease. 
             Recent cross-sectional studies showed that increased serum uric acid levels 
are reasonably increased in NAFLD and also the prevalence rate of NAFLD 
increases as the serum uric acid levels increases.  
               These results concluded that elevated serum levels of uric acid may be 
associated with the development of nonalcoholic fatty liver disease. However, 
whether this association of serum uric acid and liver disease is causal, a by stander, 
or a consequence of NAFLD still remains under debate 
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                                                   AIM OF THE STUDY 
 
 To assess the prevalence of hyperuricemia in nonalcoholic  patients with 
cirrhosis liver and fatty liver 
 To study the association of uric acid  and  various risk factors 
 To study the usefulness of serum uric acid as an prognostic marker in chronic 
liver disease 
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                                    REVIEW OF LITERATURE 
 
 ANATOMY OF THE LIVER  
 
         It is the largest intra abdominal organ in the body. It weighs about 1200 
gms to 1500gms and also it comprises one fifteenth of the body total weight 
in the adult. It is relatively larger in size in infancy and childhood compared 
to adults and measures about one eighteenth of the total birth weight. 
         Liver present and occupies in the right hypochondriam and epigastric 
region of upper abdomen. liver is a wedge shaped organ  and capsule of the 
liver plays an important role in maintaining the liver integrity. Liver is 
covered by the   chest ribs in the upper quadrant on the right side of abdomen 
hence the upper border of the human liver lies nearly at the level of the right 
side   nipple. 
         The liver anatomy describes liver in to right and left lobes, the external 
appearance of liver division into two lobes is by umbilical fissure and a 
ligament called falciform . The right lobe is much larger than left side lobe 
of liver, it is six times larger than the left lobe of liver.  The caudate lobe   is 
seen in the posterior surface of right lobe of liver and the lobe in the inferior 
surface of liver is known as the quadrate lobe. The two lobes of the liver are 
also separated anteriorly by a visible fold of peritoneum which is named as 
 
  
14 
 
the falciform ligament. Liver is a divided posteriorly by ligamentum 
venosum a fissure in liver and also inferiorly by the fissure called 
ligamentum teres. 
 Surfaces of liver  
        The liver has superior, anterior, right, posterior and inferior surfaces, 
and a distinct Inferior border, the superior, anterior and right surfaces of the 
liver are continuous and there is no definite borders to separate them. The 
borders are rounded between the right and inferior surfaces, but they angled 
more sharply between the anterior and inferior surfaces. This part of the 
inferior border of liver is notched by the ligamentum teres. The inferior 
border present in the right costal margin lateral to the gallbladder fundus. In 
the left side of the ligamentum teres, the inferior border ascends below the 
right costal margin. 
          It crosses the infrasternal angle and passes behind the medial end of 
the left costal margin. At the infra sternal angle of body the lower border  of 
the liver is in relation to the muscles of anterior abdominal wall and it can be 
very well examined by percussion.  
        In the midline of human body, the inferior border of the liver lies near 
the Trans pyloric plane and about a hand's breadth below the xiphi sternal 
joint.    
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Superior surface    
      It is the largest surface and it lies just below the Diaphragm and 
separated from it by the peritoneum except for a small triangular shape area.  
Most of the superior surface of liver lies below the right dome of diaphragm. 
The left side of the superior surface of liver lies near part of the left dome of 
the diaphragm. This surface blends with the anterior, posterior and right 
surfaces over the 'dome' of the liver.   
Anterior surface    
         This surface is approximately triangular and convex in shape and 
covered by peritoneum except at the level of attachment of the falciform 
ligament. Most of this is in contact with the anterior attachment of the 
diaphragm. In the right side the diaphragm separates this surface from the 
pleura, 6 th to 10 th  ribs and costal cartilages, and on the left side of the liver 
from the seventh & eighth inter costal cartilages. The median part of the 
anterior surface of the liver lies behind the xiphoid process and the anterior 
abdominal wall.   
Right surface  
        The right surface of the liver is covered by peritoneum and it lies near 
the right dome of the diaphragm. Above and lateral to the upper third of the 
right surface, lies the right lung and basal pleura. The diaphragm, 
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costodiaphramatic recess and the ninth and tenth ribs lie lateral to the right 
surface 
Blood supply of the liver  
        The liver has a dual blood supply. The portal vein which is formed by 
joining  superior mesenteric vein and splenic vein drain venous blood both 
from the intestines and spleen, it is a special system called portal system. 
Hepatic artery which arises as a branch from the celiac trunk or axis supplies 
blood to the liver ,it is the main arterial supply of pure blood to liver.  
        These two PV and hepatic artery gains into the liver via a fissure in Rt 
lobe.  Inside the liver porta hepatis, there are divisions of the portal vein and 
the hepatic artery into small branches which ultimately supplies both the 
lobes of liver 
Nerve supply of the liver 
       The sympathetic ganglia T7 to T10 has nerve fibers which supplies the 
liver via hepatic plexus, which in turn has synapses in the celiac plexus, the   
left vagus and right vagus nerves and the right phrenic nerve.  
 Venous drainage of liver 
     The main venous drainage of the liver is from hepatic vein which 
originates from liver as left and right hepatic veins then drain into the 
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inferior vena cava, this right and left hepatic vein carries impure    blood      
to     right    atrium via IVC (inferior vena cava) 
Lymphatic drainage of the liver  
         Lymphatic drainage of liver is usually to the node in the porta hepatis, 
which is seen along the blood vessel, some lymphatics also enter the 
mediastinum through falciform ligament and some lymphatics also enters 
thorax via inferior vena cava. 
       
DEVELOPMENT OF THE LIVER 
       The formation of liver is by endodermal bud which begins from the 
foregut, during the third or fourth week of pregnancy. This endodermal bud 
separated into two parts as hepatic part and biliary part. The hepatic part of 
the liver contains basic progenitor cells which will differentiates into 
hepatocytes or ductal cells in the formation of liver, which later develops 
into the early primitive bile duct structures. . 
       Changes of microscopic part of cells is associated with changes in the 
cytokeratin structure inside the cell. 
      The relation between proliferating cell mass in endodermal region, 
foregut and endodermal bud result in the formation of the gallbladder and 
extra hepatic biliary ducts. Bile is produced in the liver of foetus at about the 
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twelfth week of gestation. The haemaetopoietic cells are acquired from the 
septum transversum mesoderm in foetal liver, the kuffer cells and connective 
tissue cells also develops. The major haemopoietic function in foetus is by 
the liver but in adults it is taken over by bone marrow, the haematopoietic 
function of liver is grossly reduced during the intrauterine life at later stages 
that is during last two months. 
HISTOLOGY OF LIVER 
    The liver contains two types of tunnels, they are the portal canal and the 
hepatic central canal. These canals are arranged in a way, that they will not 
touch each other.  
          The sinusoids placed haphazardly, usually in perpendicular direction 
to the lines connecting the central veins of the liver. The central hepatic 
canals contain radicles of the hepatic vein, which are surrounded by a 
limiting plate of cells.  The portal triad formed by the portal vein radicle, the 
hepatic arteriole and the bile duct. 
      The liver cells comprises about 60% of the liver parenchyma. They are 
polygonal in shape and nearly 30 μm in diameter. It has a single nucleus 
mostly they multiply by mitosis. 
       The wall in the sinusoids composed of endothelial cells and phagocytic 
cells from reticulo endothelial system. The flat components in the liver are 
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known as Kupffer cells and they play an important role in the formation of 
immune bodies, phagocytosis and   blood formation. 
 The tissue space in between the hepatocytes and the sinusoidal lining cells 
are called as space of disse. It contains fluid, which flows away and into the 
lymphatics present in the portal triads. 
Electron microscopy: 
      Under the electron microscopy the cells of the liver looks straight except 
for a few anchoring pegs. From the hepatocytes the microvilli protrudes into 
the wall of the biliary canaliculi. Along with the sinusoidal border of the 
liver, the irregular sized microvillus projects into the peri-sinusoidal space 
.The nucleus contains deoxy ribonucleoprotein.  
      The mitochondria also has got two types of membranes. The inner 
membrane is invaginated and form grooves or cristae. More amount of 
energy giving processes takes place inside them particularly those involved 
in oxidative phosphorylation. 
       The rough endoplasmic reticulum are seen as lamellar profiles which are 
lined by the ribosomes. They produces specific proteins, mainly albumin 
which are used in coagulation of blood and enzymes. Triglycerides are 
formed from the free fatty acids and joins with the proteins and secreted by 
exocytosis as lipoprotein. 
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      The smooth endoplasmic reticulum of the liver forms tubules and 
vesicles which contains microsomes. It is also a site for conjugation of 
bilirubin and detoxification of many of the drugs and other compounds. 
Steroids are synthesized in this part of liver. 
        The lysosomes in liver are pericanalicular dense bodies present near 
bile canaliculi. They are also called as intracellular scavengers. The golgi 
apparatus has a system of particles and the vesicles which also lies along the 
canaliculus.  
       The sinusoidal wall consists of three types of cells. They are   
endothelial cells, kupffer cells and lipocytes. The lipocytes present in the 
space of disse between the hepatocytes and endothelial cells. The kupffer 
cells are elongated structures having irregular outline, with crenated nucleus, 
few mitochondria and varying numbers of lysosomes. Pit cells are found in 
the sinusoidal wall they contain granules and may have an endocrine 
function. 
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      Liver is one of a complex organ present in our body which has an 
interdependent metabolic, excretory and defense functions in our body.  
Many screening tests are used for detection of hepato-biliary abnormalities 
and also helps to differentiate clinically suspected disease and assess the 
severity of liver disease  
CHRONIC LIVER DISEASE 
       Chronic diseases of liver can be defined as a process of disease results in 
progressive destruction of liver and also liver parenchymal regeneration 
resulting in fibrosis leading to liver fibrosis and liver cirrhosis. 
         Because of long duration of insult to the liver, scar tissue develops 
gradually and Changes the normal functioning liver tissue and slowly 
diminishes blood supply via the liver.  
          When the original liver tissue and function is lost, the metabolism of 
nutrients, hormones, drugs, and poisons are processed ineffectively by the 
liver .In alcoholic patients the leading cause of death is due to CLD. Chronic 
liver disease occurs both in alcoholic and nonalcoholic patients. 
                                         Alcoholic liver disease 
       Abuse of Alcohol is present worldwide. Increased  alcohol intake not 
only affects the physical, mental health but also affects the financial state of 
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the people. Alcoholic liver disease is one of the leading cause of death 
nowadays. Most of the patients with advanced disease die within 48 months 
PATHOPHYSIOLOGY OF ALCOHOLIC LIVER DISEASE 
        Alcohol can produce a wide range of liver diseases from fatty change to 
hepatitis and later cirrhosis. 
Fatty change in liver 
               The metabolism of alcohol in liver invariably produces fat in the 
liver cells, mainly in zone 3. This changes are minimal with small amounts 
of alcohol. With larger amounts of alcohol intake the cells become swollen 
with fat (steatosis) giving a Swiss-cheese effect on staining with 
haematoxylin and eosin. 
            Steatosis of liver also seen in case of obesity, diabetes, starvation and 
occasionally in chronic illness. There is no damage to liver cells. The fat in 
the liver cells disappears after stopping alcohol. 
             In some cases of fatty liver collagen is deposited around the central 
hepatic veins (perivenular fibrosis) and this can progress later to 
development of cirrhosis without a previous hepatitis. 
          Alcohol has direct effect on stellate cells, which transforms them into 
collagen-producing myofibroblast cells. Cirrhosis may later develop if there 
is an imbalance between degradation and production of collagen in liver 
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Alcoholic hepatitis 
            In addition to fatty change in liver there is infiltration by 
polymorphonuclear leucocytes and hepatocyte necrosis seen mainly in zone 
3. Dense cytoplasmic inclusions which are called as Mallory bodies are 
sometimes seen in the hepatocytes and giant mitochondria are also seen.  
           Mallory bodies are only suggestive of, but are not specific for, 
alcoholic damage as they can be seen in other liver diseases, such as 
Wilson's disease and PBC. If alcohol consumption continues for longer 
period, alcoholic hepatitis later progress to cirrhosis 
Alcoholic cirrhosis 
          This is classically of the micronodular type, but can present with a 
mixed pattern .it may also be seen with accompanying fatty change, and 
evidence of pre-existing alcoholic hepatitis in liver 
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                             MECHANISM OF LIVER CELL INJURY 
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                           STAGES OF ALCOHOLIC LIVER DISEASE 
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URIC ACID IN ALCOHOLIC LIVER DISEASE 
        Increased intake of alcohol (ethanol) is associated with a significant rise 
of serum uric acid, which has a dual action.  Serum uric acid and alcohol are 
associated by many mechanisms. Alcohol increases the formation of serum 
levels of UA in liver by increasing the metabolic production of body lactic 
acid and later causes ‘lacticacidosis’.  
       The plasma concentrations of xanthine and hypoxanthine are increased 
by alcohol because of increased degradation of adenine nucleotide which is a 
weak inhibitor of the enzyme xanthine dehydrogenase. Beer also has 
contribution to purines. Ethanol decreases excretion of uric acid by 
promoting dehydration and rarely result in clinical ketoacidosis. 
                    NON ALCOHOLIC FATTY LIVER DISEASE 
NATURAL HISTORY 
          Overall, morbidity and mortality significantly and definitely higher in 
NASH patients compared to general population, in NASH patients most 
commonly death is due to Coronary artery disease and malignancy, next 
common is liver related mortality. There is significantly shorter survival in 
nonalcoholic steato hepatitis children compared to people in general 
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population with NASH,     The NAFLD natural history is determined mostly 
by the severity of the histologic damage and histologic severity. 
         Mostly benign clinical course is seen in NAFLD patients having pure 
steatosis in liver without inflammation and they usually have a benign 
course.  Patients over a period of 10 to 21 years about15 to 20% of all NASH 
patients will progress to cirrhosis related complications.   
                   When initial biopsy of liver is taken for  NASH patients one-
third will be having advanced hepatic fibrosis and another  9% to 15% will 
have quite well established cirrhosis, In patients with NASH, the major  risk 
factor in the development of hepatocellular carcinoma (HCC) is cirrhosis. 
The prevalence of hepatocellular carcinoma over a 20 year period in NASH 
and NAFLD is as follows   (a) NAFLD   0% to 0.5 % 
                                            (b) NASH 0% to 2.8% 
Now more number of cases with NASH-associated cirrhosis are under going 
 Transplantation of liver 
       The estimated 5 year and 10 year survival for patients with NASH are 
67% and 59 %.But it is very difficult to differentiate the cause of death 
whether due to liver disease or underlying cause 
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PATHOPHYSIOLOGY 
            Even after various studies the pathophysiology of NAFLD is still not 
clear. The two hit theory implicates both insulin resistance and oxidative 
stress are potential factors that leads to steatohepatitis , fibrosis and finally 
cirrhosis. 
        The “first hit” theory is excessive fat accumulation in liver hepatocytes, 
which is very closely linked to insulin resistance and obesity. In this process, 
because of increased accumulation of fatty acids steatosis develops. The 
mechanism by which steatohepatitis develops and progress to fibrosis is not 
very clear. 
          The ‘‘second hit’’ theory is the process from oxidative stress to the 
hepatocyte injury, resulting in inflammation, and fibrosis; SUA has been 
proved to be pro inflammatory and an increased SUA level reflects the rate 
of cell turnover.   
        Mitochondrial injury leads to ATP depletion reactive oxygen species 
generation, lipid peroxidation and cytokine induction which causes 
hepatocyte injury. In recent years, some study showed that SUA had strong 
antioxidant function  
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 INSULIN RESISTANCE 
          Insulin resistance is considered as an important factor in the 
development of NAFLD. Peripheral insulin resistance causes lipolysis of 
triglyceride within the adipose tissues and inhibits adipocyte uptake of fatty 
acids, both in turn, increasing the delivery of fatty acids to the liver. 
        The compensatory hyperinsulinemia causes promotion of hepatic de-
novo lipogenesis and esterification of fatty acids into triglycerides, and also 
decreases fatty acid oxidation. Hence obesity, which often leads to insulin 
resistance and presents a fatty challenge to the liver. 
       Insulin resistance and hyper insulinemia both indirectly associated with  
development of NAFLD. Insulin resistance index and insulin secretion were  
Measured using homeostasis model assessment. Patients with NAFLD have 
fasting and glucose induced hyper insulinemia and insulin resistance.  
         Insulin resistance and hyper insulinemia causes excess lipolysis which 
then causes increased levels of free fatty acids. Increased fatty acid uptake 
leads to overload of mitochondrial beta oxidation and leads to accumulation 
of fatty acids in hepatocytes. 
         Due to a suppression of TNF-alpha production and also an antagonism 
of its function, in that adiponectin and TNF-alpha elicit many opposite 
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functions, for example, TNF-alpha being a causative factor of insulin 
resistance, whereas adiponectin increases insulin sensitivity.  
        Similarly, TNF-alpha is a proinflammatory cytokine, whereas 
adiponectin has direct anti-inflammatory effects. Although the primary 
etiology of NAFLD and ALD is different, these liver diseases apparently 
share similarities in disease progression. 
The hepatic consequences of insulin resistance are: 
1. Increased lipogenesis via insulin:  
       Insulin directly up-regulates the transcription and proteolytic     
maturation of the transcription factor SREBP-1c. This action is 
independent of the insulin receptor (IRS-1) that mediates insulin’s 
glucose influence 
 2. Increased lipogenesis via hyperglycaemia:  
       The elevated glycaemia directly up-regulates nuclear translocation of 
carbohydrate responsive element binding protein ( CHREBP). CHREBP acts 
in synergy with SREBP1c to further inducing the lipogenic gene expression 
and to provide the precursors for lipogenesis by also inducing glycolytic 
gene expression 
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3. Increased NEFA delivery to the liver:  
      Adipocytes are normally extensively insulin sensitive. Adipocyte insulin 
resistance results in a reduced suppression of lipolysis, and thus an increased 
NEFA release into the circulation and hepatic uptake 
4. Decreased VLDL excretion: 
       Insulin attenuates apolipoprotein B, and hence VLDL, formation. This 
impairs hepatic triglyceride exportation ability. The mechanism behind this 
frequently observed phenomenon has not been fully determined, though may 
it occur via microsomal triglyceride transfer protein (MTP) down regulation. 
           MTP is a critical determinant of triglyceride and apolipoprotein B 
incorporation into VLDL and its subsequent plasma excretion. MTP-specific 
inhibition reduces plasma triglycerides and VLDL, whilst increasing hepatic 
triglycerides 
           From the above actions it is clear that insulin resistance is a key factor 
in hepatic lipid balance and steatosis development. When vigorously 
assessed most non-diabetic NAFLD patients have sub-clinical insulin 
resistance with evidence of impaired glucose peripheral uptake. Sub-clinical 
 Systemic and hepatic insulin resistance correlates strongly with intra-hepatic  
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steatosis. Most NAFLD patients do not have overt systemic insulin 
resistance i.e. type 2 diabetes, and only around 50% of type 2 diabetics have 
NAFLD 
OXIDATIVE STRESS 
        It is unclear why only some patients develop NAFLD alone and others 
develop hepatic fibrosis and cirrhosis. Mitochondria is thought to be the 
major source of reactive oxygen species which leads to development of 
steatohepatitis through lipid peroxidation and cytokine induction. 
          Mitochondrial swelling and damage results in impaired ATP 
resynthesis and depletion of ATP. Inflammation and hepatocyte damage also 
causes recruitment of inflammatory cells, induction of cytokine and 
generation of reactive oxygen species from neutrophils and macrophages. 
          One of the most advocated mechanisms that could explain why 
alcohol and obesity, potentiate each other in progression from fatty liver to 
steatohepatitis and fibrosis, is oxidative stress.  
         Although some degree of oxidative stress can be seen in the steatosis of 
most etiologies. It is believed that an alternative or extra source of oxidative 
stress is needed to escape the cellular defense systems and to progress from a 
fatty liver. 
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            Insulin resistance has been suggested as being capable of playing the 
roles of both the first and the second hit, as it often leads to fatty liver, which 
further decreases insulin sensitivity.  
          The connections between insulin resistance, steatohepatitis and 
oxidative stress have been supported by the observations that individuals 
with NASH are significantly more insulin resistant than those with a fatty 
liver alone and the oxidative damage is more pronounced in NASH than in 
simple steatosis 
       Non-alcoholic fatty liver disease (NAFLD) is a very quiet common 
disorder and includes a group of conditions results in increased hepatic fat 
accumulation in the absence of significant alcohol consumption the causes 
are like viral infection, some diseases causing some specific changes to liver 
pathology. 
            Nonalcoholic fatty liver disease commonly causes chronic liver 
disease, which has many etiological factors like genetic, environmental, 
metabolic, and stress-related components. The most common form of 
NAFLD is called as fatty liver. In fatty liver, accumulation of fat occurs in 
the liver cells.  
         A small group of people with non-alcoholic fatty liver disease may 
develop a more serious condition named Non-alcoholic steatohepatitis 
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(NASH). In NASH, accumulation of fat is associated with inflammation of 
liver cells and varying amount of scarring. 
        NASH is a very serious condition which may leads to severe liver 
damage and cirrhosis. Cirrhosis occurs when the liver damage is extensive 
and the liver cells are slowly replaced by scar tissue which makes the liver 
unable to function properly. The microscopic picture of NAFLD is much 
more similar to liver disease that is produced due to increased alcohol intake. 
           NAFLD is associated more commonly with obesity, insulin 
resistance, dyslipidemia and metabolic syndrome. NAFLD has clinical 
important because of its increasing prevalence throughout the world and it’s 
potential to progress to advanced cirrhosis and hepatic failure 
          In recent years, many studies shows an association between elevated 
serum uric acid concentrations and its association with further development 
of chronic liver disease in patients with NAFLD has been reported .  
        Some people concluded that increased uric acid level is an independent 
risk factor for the development of NAFLD, and is also related to its 
histologic severity. 
        Identifying the risk factors is very much essential for the prevention of   
development of NAFLD. The development of NAFLD has various levels of 
physiologic and biochemical stages, which includes genetic, environmental, 
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metabolic, and stress-related factors. The exact risk factors for the 
development of NAFLD in not yet identified properly.  
       NAFLD also considered as a part of metabolic syndrome. Recent 
researches are focusing on many factors that contribute to the future 
development of NASH.  
      Some of the risk factors are Oxidative stress, production and release of 
toxic inflammatory proteins like cytokines by the patient’s own 
inflammatory cells, liver cells, or fat cells which later causes necrosis of liver 
cell or death.  
EPIDEMIOLOGY OF NAFLD 
       NAFLD becoming one of the most prevalent liver diseases affecting 
people in Western countries. Now a days, this disease affects 20%–30% of 
the general population approximately.  
         NAFLD is one of the emerging problems affecting people in the Asia-
Pacific region and the prevalence is increasing gradually. Simple fatty liver 
is generally a benign condition, but when it leads to development of NASH 
in these patients later it can progress to the development of cirrhosis of liver 
and liver failure and the 5-year survival rate in these patients approximately 
ranges about 67%. 
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       Non-alcoholic fatty liver disease (NAFLD) is a main cause of 
development of chronic liver disease throughout the world.  NAFLD 
prevalence in Indian population ranges from 5 to 28%, which is comparable 
to the West.  
        Compared to the West, Indians develop NAFLD at lower degree. 
Because of the change of lifestyle and diet structure, increased incidence of 
NAFLD has become a very serious public health problem in the world. It is 
not only a major killer in western countries, but also the serious health 
problem in Asia. 
          Present in approximately 20 to 30 % of patients in western countries 
and in Asia it is around 12 to 24%. But the exact prevalence of this disease is 
not known which may be higher than this.   
        The most common cause of abnormally elevated liver enzymes in 
patients who has asymptomatic liver disease is NAFLD. NAFLD most 
commonly seen in fifth or sixth decade of patients. It also associated with 
other diseases like diabetes mellitus, obesity and dyslipidemia. 
       Nonalcoholic fatty liver disease is most commonly seen among men 
than women in all age groups up to the age 60 years. This is because of the 
protective nature of estrogen. 
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GRADING OF NAFLD 
     GRADE 1:  MILD 
                  Steatosis-mostly as macro vesicular     
                 Ballooning-occasionally seen in zone 3 
                  Inflammation of the lobules-mild acute and chronic inflammation 
with neutrophils and monocytes respectively inflammation of the portals- 
ranges from none to mild 
GRADE 2: MODERATE 
               Steatosis -any degree, mixed 
              Ballooning-in zone 3 
              Lobular inflammation-neutrophils maybe associated with ballooned  
               hepatocytes with or without inflammation 
               Inflammation of the portals- ranges from mild to moderate 
GRADE 3: SEVERE 
              Steatosis-greater than 66%.mixed 
             Ballooning-marked. Predominantly in zone 3 
            Lobular inflammation-scattered acute and chronic inflammation 
            Portal inflammation-mild to moderate 
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STAGING 
            Requires Masson trichrome or equivalent stain 
            Stage 1: 
                 perivenular, perisinusoidal or pericellular fibrosis in zone 3 
                fibrosis maybe focal or extensive. 
       Simple fatty liver (steatosis). Here increased amount of fat globules 
builds up inside the liver cells, but is usually thought as harmless. People 
usually does not have any symptoms. People may not even know this until 
they get an abnormal blood test result 
Stage 2: 
              Stage 1 with focal or extensive portal fibrosis. It is also known as      
non-alcoholic steatohepatitis (NASH) 
          Only a small number of people with simple fatty liver later develop 
stage 2 of the condition, which is called as non-alcoholic steatohepatitis 
(NASH). 
       NASH is a more aggressive form of the disease. In this disease the liver 
has become inflamed. Inflammation is one of the part of the body's response 
 
  
46 
 
to injury. People with NASH may experience a very dull or aching pain in 
the top right side of their abdomen 
Stage 3: 
            Bridging fibrosis .focal or extensive.  
Some of the people with NASH develop fibrosis, here constant inflammation 
in the liver cells results in the formation of fibrous tissue around the liver 
cells and blood vessels. 
Stage 4: 
             Cirrhosis with or without peri sinusoidal residual fibrosis formation 
This is the very severe stage. Here the liver cells has bands of scar tissue and 
clumping of liver cells. The liver reduces in size and becomes like a lump. 
            Cirrhosis usually occurs after 50-60 years of age following longer 
duration of inflammation of the liver associated with the early clinical stages 
of the disease.  
          But, this also can develop much earlier in some people. Patients with 
type 2 diabetes mellitus are at greatest risk of developing cirrhosis caused by 
NAFLD. Cirrhosis of liver causes permanent liver damage. 
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RISK FACTORS AND CONDITIONS ASSOCIATED WITH NAFLD 
METABOLIC 
         Obesity 
         Type 2 diabetes mellitus 
         Hyperinsulinemia 
         Rapid weight loss including starvation and bypass surgeries 
        TPN 
        Lipodystrophy 
MEDICATIONS 
      CARDIAC: 
                      Amiodarone 
                      Calcium channel blockers 
                     Aspirin 
      STEROIDS: 
                        Glucocorticoids 
                         Synthetic estrogens 
     ANTIMICROBIALS: 
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                        Tetracycline 
                        Antivirals such as zidovudine and didanosine 
   OTHERS: 
                  Tamoxifen 
                 Valproic acid 
                 Methotrexate 
                 Cocaine 
OTHER CONDITIONS: 
               Inflammatory bowel disease 
              Small intestinal diverticulosis with bacterial overgrowth 
              HIV infection 
               Bacillus cereus infection 
 
EPIDERMIOLOGY OF MAJOR RISK FACTORS: 
            Obesity-30 to 100 % 
           Type 2 diabetes mellitus-34 to 75 % 
           Hyperlipidemia-20 to81 % 
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HEPATIC FATTY ACID METABOLISM IN HEALTH  
           The liver is the key organ in determining the metabolism and 
distribution of fatty acids. It is the source of endogenous synthesis and 
degrades or interconverts exogenous fatty acids. 
         The resultant fatty acids may either be stored in the liver itself, or 
exported to adipose tissue and muscle. Hepatic fatty acid metabolism is 
dynamic with triglyceride turnover occurring every 2 days  
         Circulating fatty acids are either bound to lipoproteins or albumin. 
Lipoprotein-bound lipids, which include chylomicron complexes, are 
internalized into cells following the formation of a specific apolipoprotein-
receptor complex. 
         Dietary medium-chain triglycerides enter the portal circulation directly, 
whereas longer chain fatty acids enter the vascular circulation complex with 
chylomicrons via the lymphatic system and the thoracic duct 
           Historically it was believed that in contrast to lipid-lipoprotein 
complexes, the albumin bound NEFAs are internalized into cells via simple 
and direct penetration of the plasma membrane.  
          The recently discovered cluster differentiation protein 36 (CD 36) 
forms a pathway for hepatic fatty acid uptake which is up regulated by  
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Insulin and experimental models of NAFLD. 
                As a result NEFAs are the key fatty acid source for the liver with 
an uptake that is directly proportional to its delivery rate (Havel, Kane et al. 
1970) and potentially increased by insulin resistance and NAFLD.  
            The concentration of circulating NEFAs is dependent on their release 
from adipocytes and myocytes. This is regulated by hormone sensitive lipase 
which is stimulated by adrenaline, and inhibited by insulin  
           Insulin also acts to reduce circulating glucose concentrations by 
promoting its tissue uptake. Insulin resistance however results in increased 
circulating concentrations of insulin, and the principal hepatic fatty acid 
substrates, namely glucose and NEFA. As a result insulin resistance 
promotes hepatic lipogenesis. 
           Intra-hepatic fatty acids are cytotoxic and so are further metabolized 
by three potential and separate processes: either beta-oxidation, VLDL 
synthesis or intra-hepatic storage as triglycerides.  
           In the presence of high energy demand, intra-hepatic fatty acids 
undergo oxidation to generate energy in the form of ATP. If there is a low 
energy demand then intra-hepatic fatty acids are esterified into triglycerides 
and either stored in the hepatocyte or exported as VLDL. 
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1.Oxidation 
    Within the mitochondria fatty acids in the form of acyl-CoA molecules are  
Progressively cleaved by β-oxidation to generate ATP. The process is 
initiated at the carboxyl end and involves the successive disruption of the 
link between the α-2 and β-3 carbon atoms (Lavoie and Gauthier 2006).  
         At the end of each cycle the chain is reduced by two carbon atoms, and 
one molecule of FADH2, NADH and acetyl CoA is produced. The acetyl-
CoA is then further oxidized within the mitochondria via the citric acid 
cycle, while the FADH2 and NADH enter the electron-transport chain. The 
process is repeated until the whole chain is oxidized. 
            Microsomal (α and ω) oxidation occurs within the endoplasmic 
reticulum by members of the cytochrome P450 family. They catalyze the 
oxidation of a variety of exogenous and endogenous compounds and play a 
relatively minor role in fatty acid oxidation 
2. VLDL synthesis 
          The addition of a single glycerol molecule to three fatty acids forms a 
triglyceride. Triglycerides cannot freely cross hepatocyte membranes, and so 
are either stored within the hepatocyte itself, or are coated in lipoproteins, 
incorporated within VLDL, and exported into the systemic circulation.     
VLDLs are formed within the liver and are a complex fusion of lipoproteins 
 
  
53 
 
Apolipoprotein B-100), lipids and phospholipids. VLDL secretion facilitates 
the transfer of intra-hepatic fatty acids to peripheral adipose stores 
3. Storage within the hepatocytes 
         The final option for fatty acids is of conversion to triglycerides and 
storage within the hepatic cytosol. Factors that directly promote hepatic 
triglyceride storage are poorly understood. Intra-hepatic storage appears to 
occur when fatty acid production exceeds the liver’s oxidation or exportation 
abilities. 
LIPOPROTEIN  
 Definition:  
           Lipids synthesized in liver and intestine are insoluble.  They are 
Transported to many tissues in the body for metabolic functions through 
formation of macromolecular complexes called as Lipoproteins. 
         These are spherical shaped particles with the nonpolar lipid core 
containing Triglycerides and cholesterol esters. Peripheral polar lipid 
contains phospholipids and free cholesterol present near the surface.  
         They contain specific proteins which are called as Apo lipoproteins 
present on surface. They are attached none covalently through hydrogen 
bond and Vander Waals forces. Binding of lipids to protein is very loose 
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which allows ready exchange of lipids among the plasma lipoprotein and 
between cell membranes and lipoprotein 
Type of Lipoproteins: 
   Lipoproteins are based on hydrated densities, separated by ultra-
centrifugation. They are 
  Chylomicrons 
  Very low Density Lipoprotein 
  Intermediate Density Lipoprotein 
  High Density Lipoprotein 
  Lipoprotein a. 
Apo lipoproteins:  
     It is a protein component of lipoproteins. It is present in various 
proportions in all types of lipoprotein. 
Apo A-I, Apo A-II, Apo A IV 
Apo B-100, Apo B-48 
ApoC-1, ApoC-II, ApoC-III 
Apo-E, 
Apo (a) 
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 Metabolism of Lipoprotein 
    The Pathways of lipoprotein metabolism are 
1) Exogenous pathway  
2) Endogenous pathway 
3) Intracellular LDL receptor pathway 
4) HDL Reverse – Cholesterol pathway 
1. Exogenous Pathway (Chylomicron): 
  Lipoprotein is mostly of dietary origin. Dietary triglycerides and 
Cholesterol esters are arranged in secretary vesicles inside the Golgi 
apparatus to form nascent chylomicrons.  
           Chylomicrons is introduced into circulation through intestinal villi. Its 
lipid content is about 90% of Triglyceride and 2% of Apo B and Apo A. This 
Nascent chylomicron acquires Apo C and Apo E from high density 
lipoproteins to form Chylomicron. 
        Apo C-II present on the surface of chylomicron activates lipoprotein 
lipase, which is attached to luminal surface of endothelial cells of intestine. 
Lipoprotein lipase hydrolysis triglycerides to free fatty acids, which then 
taken up by the muscles for energy and adipose tissue for storage. 
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 Apo A, some phospholipids and free cholesterol are transferred from 
chylomicron to high density lipoprotein.  
              Thus new chylomicron which is formed is called chylomicron-
remnant, which contains TGL, Apo B-8 & Apo E. Presence of Apo B-48 and 
Apo E is recognized by a specific hepatic remnant receptor which is 
internalized by endocytosis. 
             Lysozymes hydrolyses chylomicron remnants to form bile acids. 
Chylomicron is incorporated into newly formed lipoprotein or stored as 
cholesteryl ester 
2. Endogenous Pathway: 
        Lipoprotein is purely of hepatic origin, Triglycerides and Cholesterol 
can also be synthesized in liver. Endogenous Triglyceride and cholesterol are 
packaged in secretary vesicles in Golgi apparatus which is transported by 
exocytosis into extra cellular fluid and then into the circulation, in the form 
of    Nascent very low density lipoproteins, containing 55% TGL and Apo B-
100, Apo E and also small amount of Apo C on its surface.  
              Additional Apo E and Apo C are transferred from circulating high 
density lipoproteins to nascent VLDL forming very low density lipoproteins.  
Apo II present on surface of VLDL activates lipoproteins on endothelial 
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cells and also hydrolysis VLDL & TGL releasing free fatty acids and 
glycerol. 
           During hydrolysis Apo C is transferred back to high density 
lipoproteins. VLDL is converted to VLDL remnants & are taken up by liver 
and rest are converted to intermediate density lipoproteins. IDL has Apo E 
on surface, hence it binds to hepatic remnant receptor removing nearly 50% 
of IDL.  
          Some materials from intermediate density lipoproteins that is 
phospholipids, free cholesterol, and apolipoprotein are transferred to high 
density lipoproteins to form HDL-De nova. Cholesterol esters are transferred 
from high density lipoproteins to low density lipoproteins. 
         The net result of lipolysis and cholesterol esters exchange is 
replacement of triglyceride core of very low density lipoproteins with 
cholesterol esters. Further intermediate density lipoproteins undergoes 
lipolysis removing the remaining triglycerides and all Apo lipoproteins 
except B-100 to form low density lipoproteins. 
3. LDL receptor Pathway: 
   There are specific receptors which are present in coated pits of plasma 
membrane, which recognize and bind to ApoB 100 of LDL. The particles are 
internalized in coated vesicle to form endosome, receptor dissociate from 
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low density lipoproteins and return to cell surface. Low density lipoproteins 
migrate to lysosome, ApoB 100 is degraded to small peptides and amino 
acids. 
           Cholesterol esters are hydrolyzed and free cholesterol is available for 
synthesis of cell membranes, steroid hormones and bile acids. 
Increased supply of free cholesterol leads to: 
1. Decreased rate of synthesis of endogenous cholesterol by inhibiting rate 
limiting enzyme HMG-COA reductase.  
2. Increased formation of cholestryl esters catalysed by ACAT. 
3. Inhibition of the Synthesis of new low density lipoprotein receptors by 
inhibition of transcription of receptor gene. 
          Low density lipoproteins is also taken up by extra hepatic tissues 
through scavenger receptors or non-receptor mediated pinocytosis. The non-
receptor mediated uptake become important as plasma concentration 
increase as in the case of familial hypercholesterolemia. 
          Non receptor mediated uptake is not saturated or regulated. Scavenger 
receptor is also unregulated, found in macrophages and other cells. 
Macrophages engorge cholesteryl esters to form foam cells, considered the 
earliest component of atherosclerotic lesion.2/3 rd. of low density 
 
  
59 
 
lipoproteins is removed by low density lipoproteins receptors and remaining 
by scavenger cell system 
BODY MASS INDEX 
The most commonly used method for assessing obesity. 
 Body mass index (BMI) is defined as weight in kilograms divided by the 
square of height in metre    (kg/m2)  
 
According to the recommendations by the World  Health Organization 
(2000),BMI of less than  18.50 kg/m2 denotes underweight, BMI  of 18.50–
24.99 kg/m2 normal weight, BMI of 25.00–29.99 kg/m2 overweight, and 
BMI of 30.00 kg/m2 obesity. In Asian and Pacific area populations, a 
specific BMI reflects a higher percentage of body fat compared to same BMI 
in Europeans. 
BMI Prime 
        It is a simple change in the BMI measurement system. It is defined as 
the ratio of actual body mass index to the upper limit of BMI (currently 
defined at BMI 25). As defined above it is also defined as the ratio of the 
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body weight to its upper body weight limit, which is calculated at BMI 25. 
As it is a ratio of two separate body mass index values, the BMI Prime is 
defined as a dimensionless number without any associated unit. People  with 
body mass index Prime lower  than 0.74 are called as underweight, those 
people between 0.74 and 1.00  are called optimal weight and those people 
the level 1.00 or greater are called as overweight.  
      BMI Prime is more clinically useful because the individuals can tell, by 
what percentage they are deviated from their upper limit of weight. For 
instance, persons with the BMI of 34.00 have a BMI Prime of 34/25 = 1.36, 
and this is nearly 36% higher than his or her upper limit of body mass index. 
    In South East Asian populations and South Chinese populations the BMI 
Prime level should be calculated using an upper limit body mass index of 23 
in the denominator instead of 25 which is commonly used. BMI Prime helps 
in easy comparison of populations in various countries and whose upper 
limit BMI values changes or differ 
Categories 
    An important use of the body mass index is to assess, how the individual's 
body weight varies from the desirable or normal for his or her height and 
weight. The excess weight or reduced weight accounted for amount of fat in 
the body, even though other factors such as increased musculature also 
affects the BMI significantly. The WHO classifies the people if the BMI of 
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less than 18.5 as underweight, which indicates the   person maybe having 
malnutrition or eating disorder, or some other health problems. If the BMI of 
a person is greater than 25 it is considered as overweight and BMI above 30 
is considered as obese. These ranges of BMI values are valid and also as 
statistical categories 
 
 
Waist circumference 
         It is a method for detecting obesity and its related risks. It is widely 
accepted that central obesity is more detrimental than peripheral obesity, 
waist circumference is often a better predictor of diseases than BMI. The cut-
off points for elevated waist circumference should be population and country 
specific. 
        The circumference of waist is calculated strictly at the level midway in 
between the lowest rib on both sides and the iliac crest of the hip. The waist 
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hip ratio is calculated by dividing the waist circumference by the hip 
circumference. But usually the waist circumference is measured at the level 
of smallest circumference of the natural waist in the body which is usually 
just above the level of belly button.  
     If  the shape of the  waist is convex than concave, for example in  case of  
patients with pregnancy and obesity, the waist is  measured at the  vertical 
level which is  one inch above the  level of navel. 
        The measurement of size of a person’s waist circumference usually 
indicates the development of abdominal obesity. Increased levels of 
abdominal fat is also an important risk factor for future development of heart 
disease and other obesity related diseases. The National Heart, Lung, and 
Blood Institute (NHLBI) classified that the risk of development of obesity 
related diseases is much high if the men have the waist circumference of 
more than 102 cms or 40 inches and women who have the waist 
circumference of more than 88 cm or 35 inches 
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Laboratory tests 
          Advanced liver disease produce abnormalities in several laboratory 
markers. The measurements of serum liver enzymes serve as important 
diagnostic information. Serum uric acid is not a liver marker per se, but is 
included because of its role as a possible indicator of oxidative stress. 
1. Gamma-Glutamyltransferase (GGT) 
        Serum Gamma-glutamyltransferase (GGT) is an enzyme derived from 
the liver, the changes in its activity used to monitor excessive alcohol 
consumption for several decades. 
       In fact, GGT has been the most commonly used laboratory marker of 
heavy drinking. it may also elevated  due to diabetes mellitus, obesity, 
pancreatitis, hyperlipidemia, cardiac insufficiency, severe trauma, nephrotic 
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syndrome, renal rejection, and medication, and in patients with other than 
alcoholic forms of liver diseases. Non-ethanol related liver changes usually 
do not show profound changes in their GGT in the short-term.  
           Documentation of decreased activity can be helpful in the differential 
diagnosis in pointing toward alcohol etiology, markedly increased GGT 
activities are usually considered to reflect tissue damage when they 
associated with abnormalities in other liver enzymes. 
           Mild elevations of GGT relate to its biological function to maintain 
the intracellular levels of glutathione and also to metabolize glutathione 
conjugates. Glutathione is an important antioxidant, ant its removal causes 
loss of viability. 
         In general oxidative stress is associated with diseases of the modern 
life which includes cancer, neurodegenerative diseases, rheumatoid arthritis, 
atherosclerosis, NAFLD, obesity, diabetes, the metabolic syndrome, and 
others. 
2. Aminotransferases (ALT, AST) 
        Aminotransferases are measured primarily to assess the condition of the 
liver. Serum alanine aminotransferase (ALT) originates specifically from the 
hepatocytes, whereas aspartate aminotransferase (AST) can also arise from 
heart and skeletal muscle tissue. 
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             In an asymptomatic patient, the activities of serum aminotransferases 
may be increased  due to alcohol abuse, chronic hepatitis B ,hepatitis C, 
Medication , steatosis and NASH, hemochromatosis, autoimmune hepatitis, 
Wilson's disease (<40 years), alpha1-antitrypsin deficiency,  genetic errors in 
muscle metabolism, celiac sprue acquired muscle diseases, and strenuous 
exercise.  
        Aminotransferases also seem to associate with general health so that 
ALT appears to have a much stronger association with BMI than with 
alcohol consumption. ALT associates mainly with the hepatic fat content, 
and thus with NAFLD which, as a component of the metabolic syndrome, is 
highly related to the development of type 2 diabetes. 
        Elevated serum ALT in NAFLD may be a consequence of leakage from 
the damaged hepatocytes or due to increased gluconeogenesis in the absence 
of insulin. 
3. ULTRASONAGRAM 
       It is a noninvasive method of investigation. Abdominal scan in case of 
liver disease shows various information regarding size and shape of the liver, 
echogenicity of the liver, fluid collections inside the body cavity, portal vein 
size and also information’s regarding other abdominal organs 
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4. SERUM URIC ACID 
 
 
Background  
        Uric acid is the end and final product of metabolism of purines in 
human.   Even though the uric acid was first found nearly more than 200 
years ago, some of the clinical aspects of hyperuricemia are not yet clearly 
understood.  
       For so many years increased uric acid levels has been identified with or 
thought as same as the disease gout. But now increased uric acid is one of 
the risk factor for numerous metabolic and also some abnormalities of 
hemodynamic system. 
    Allantoin, which is end product of purine metabolism is seen in lower 
animals is very much soluble but uric acid is a   poorly soluble end product 
seen in humans.  
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    Human beings have an increased levels of uric acid, due to the deficiency 
of the hepatic enzyme known as uricase and also due to a lower fractional 
excretion of uric acid by kidneys. 
     About 2/3 of total urate in humans is produced by the body is by 
endogenous means and the balance one third urate is due to the intake of 
dietary purines. Nearly 70% of the urate produced in body of humans   is 
excreted daily mainly by the kidneys and the rest is removed by the human 
intestines. 
    However in cases of renal failure in humans, the intestinal excretion of 
urate excretion increases. The uric acid levels in the blood are the indications 
of the function of the balance between the purines breakdown and also the 
rate of uric acid elimination from the body. 
     So alterations in this balance which is increased intake and decreased 
elimination may theoretically contribute for the development of  
hyperuricemia ,but  Clinically there is only the  defective elimination  
accounts in  most of the cases of hyperuricemia. 
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Patho physiology 
Saturated Uric acid in the blood is about 6.4-6.8 mg/dL and in   standard 
conditions, the upper limit of solubility is about 7 mg/dL. Urate in humans is 
freely filtered by the kidneys. It is reabsorbed in the glomerulus, again 
secreted and then again reabsorbed in the proximal convoluted tubule in the 
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kidneys.  Cloning of the certain types of urate transporters  recently gained 
importance in the  understanding of  mechanisms by which the urate in the 
humans are  handled  both by the kidneys  and the  small intestines. 
         A urate anion exchanger known as URAT1 has been found in the brush 
border membranes and this is well blocked by the drug an angiotensin II 
receptor blocker, called losartan.  
       Another transporter a human organic anion transporter (hOAT1) also 
found to be blocked by both the uricosuric and the anti uricosuric drugs 
Transporter UAT also found to increase the urate efflux out of the human 
cells. These cell transporter may also account for the reabsorption and 
secretion by the kidneys 
        However the secretion of urate   correlated well with the serum levels of 
urate because even a very minimal increase in the serum concentration of 
urate causes a marked increase in urate excretion by the kidneys. So 
increased uric acid levels may occur because of decreased excretion or 
increased production or may be a combination of two 
      Reduced excretion of urate is the most common cause of hyperuricemia 
in humans. Alteration in uric acid excretion may results in decreased 
glomerular filtration and decreased tubular secretion or there may be an 
enhanced tubular reabsorption. 
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          But decreased filtration of urate usually does not cause primary 
hyperuricemia, but it can contribute to the increased uric acid levels in renal 
failure. 
         Decreased tubular secretion of urate seen in conditions with acidosis 
like diabetic ketoacidosis, salicylate or ethanol intoxication and starvation 
ketosis.  
           The organic acids which can accumulated in these above conditions 
compete with the urate for tubular secretion. Increased reabsorption of uric 
acid distal to the site of secretion is the main mechanism to be responsible 
for the increased uric acid levels observed in diuretic therapy and in patients 
with diabetes insipidus. 
           Increased production of urate accounts for only a minimal number of 
patients presenting with increased uric acid levels.  
The causes for increased serum uric acid levels in overproducers may be due 
to exogenous diet rich in purines or maybe endogenous due to increased 
breakdown of purine nucleotide.  
           Only a very small percentage of urate overproducers have defects in 
their enzymatic levels which accounts for their overproduction of uric acid. 
This includes a complete absence of the enzyme hypoxanthine guanine 
phosphor ribosyl transferase (HGPRT) as seen in Lesch Nyhan syndrome or 
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partial deficiency of HGPRT as in Kelley-Seegmiller syndrome and 
increased production of 5 phospho alpha-d-ribosyl pyrophosphate (PRPP). 
            Increased   degradation of purines may result from increased cell 
proliferation and turnover as in blast crisis of leukemia or from cell death as 
is rhabdomyolysis or cytotoxic drug therapy. Glycogenoses type III, type IV, 
and type VII can also result in increased uric acid levels due to increased 
degradation of skeletal muscle ATP. 
          Combined mechanisms of reduced excretion and increased production 
of urate can also cause increased uric acid levels. Most common cause of this 
group is increased alcohol intake, which then results in increased hepatic 
breakdown of ATP and the production of organic acids which will compete 
with the urate for tubular secretion.  
          Enzymatic defects such as glycogenoses type I and aldolase B 
deficiency are some other causes of increased levels of uric acid that result 
from a combination of increased production and defective excretion.  
           Now new findings showed that urate crystals can also be incorporated 
in an intracellular pattern recognition receptor known as macromolecular 
inflammasome complex. NALP3 (cryopyrin),NALP3 inflammasome may 
also result in the production of interleukin 1 beta  which, in  turn starts  an 
inflammatory response Inhibition of this pathway also  has a potential to  
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targeted for increased uric acid levels   induced crystal arthritis and 
development of new drugs 
Frequency  
     A  study  about uric acid in japan  ascertain 10 year database trends in the 
prevalence of hyperuricemia confirmed  that  prevalence of increased uric 
acid in  japan associated with many diseases 
     When this data is analyzed and stratified by age, the prevalence of uric 
acid levels increased among people older than 65 years in both male and 
female. In people younger than 65 years of age men had a higher prevalence 
of 4 times than that of women in that age group.  People who are older than 
65 years the gender gap is narrowed and the female-to-male ratio of 1:3, with 
gout or with hyperuricemia. 
Race 
 There is an increased prevalence of hyperuricemia seen in indigenous races 
of humans who are living in the Pacific region, which is appears to be 
associated with a reduced fractional excretion of uric acid in them. Africo 
American patients develop increased uric acid levels more commonly than 
the white persons. 
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Sex 
         Men are far more commonly affected by Hyperuricemia than Women. 
In gouty arthritis only about 5% of patients are female even though they 
have increased uric acid levels. Increased uric acid levels in women 
population after the menopause. 
Age 
The upper limit of the reference levels of uric acid for children is 5 mg/dl. or 
0.30 mmol/L. The upper limit of the reference values of uric acid for men is 
7 mg/dL or 0.42 mmol/L and for women is about 6 mg/dL or 0.36 mmol/L.  
As the age advances there is a tendency to develop hyperuricemia in both 
sex. The normal serum uric acid level is lower in children compared to 
adults. 
Total body content in average adult is 1.2 g 
Plasma uric acid is 3.5 – 7mg/dl in males and. 2.7 – 6.5 mg/dl in females 
Average Adult excretes 400 – 600 mg in 24 hrs urine 
On low purine diet 275 – 600 mg is excreted in 24 hrs urine. 
On high purine diet up to 1gm in 24 hrs urine. 
In Gout increase to 18000 – 30000 mg (total content) 
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Sources of uric acid 
 People may present with increased uric acid levels due to hereditary 
reasons.  Diet may also act as factor for high uric acid. Increased levels of 
purines are seen in many animal food products, especially in the internal 
organs like intestine.   
      High purine resources includes sweetbreads, anchovy sauce, brains, beef 
kidneys, liver, sardines, extracts of meat like Oxo, Bovril, mackerel, 
scallops, gravy and game meats, beef, pork, poultry, fish ,seafood, asparagus, 
cauliflower, green peas, lentils, spinach, mushrooms, peas which are dried, 
oatmeal  beans, wheat bran and wheat germ.  
       Moderate food intake of purine rich food is not usually associated with 
an increased risk of development of gout. Serum uric acid levels are also 
increased due to increased fructose intake, reduced excretion by the kidneys, 
and increased intake of dietary purine. 
      Fructose which are found in processed foods and soda beverages and 
also in the form of corn syrup also has increased risk.  
Laboratory test 
 Uric acid by phosphotungstic acid method 
 Method of caraway. 
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Principle:  
The procedure is based on oxidation of uric acid by phosphotungstic acid  
Reagent in alkaline medium. Phosphotungstic acid itself gets reduced to 
tungsten blue. Sodium bi carbonate is used as alkali. The amount of tungsten 
blue formed is estimated at wavelength from (690-710nm) 660nm 
Reagents 
1) Sodium tungstate 10% - 100 gm. of sodium tungstate per litre of water. 
2) 2/3 N Sulphuric acid – 18.8 ml of concentrated sulphuric acid per litre 
Of water. 
3) Tungstic acid  has  50ml of 10% tungstate +  50 ml of 2/3 Sulphuric acid 
(H2SO4) then Add drop of phosphoric acid, and mix it in 800ml water  then 
Preserved in  bottles which are brown colour. 
Phosphotungstic acid is 50g of sodium tungstate in about 400ml of 
water then Add 40ml of 85% phosphoric acid and reflux it gently for 2hr and 
Cool them and then transfer to 500ml flask and make it up to mark with 
water then the concentrated phosphotungstic acid is diluted to dilute 
phosphotungstic acid 1 to 
10 for use and should be Kept in brown bottle. 
5) Sodium carbonate 10% - 100gm of sodium carbonate in 1000ml of D/W 
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6) Standard Solution: Weigh out 100mg of uric acid in a small beaker. 60 
mg of lithium carbonate is dissolved in 15-20 ml of D/W in a test 
tube then heat the test tube to about 600°C and pour on to uric acid 
Solution. Stir until dissolved, then heated further.  
    When dissolved, transfer with washing to 100ml flask. Add 2ml of 40% 
formalin. Then slowly with shaking, add 1ml of 50% acetic acid make up to 
mark with water and mix. Stored in well stoppered bottle away from light. 
7) Working standard: Dilute 2ml of stock standard to 200ml of D/W 
Procedure           Deproteinisation: Add while shaking 5.4ml of dilute 
tungstic acid to 0.6 ml serum and centrifuge. Out of this take 3ml of 
supernatant and add 0.6 ml of sodium carbonate and 0.6ml of 
phosphotungistic acid .Mix and take OD after 30min at 700nm or red filler. 
     Similarly take 3ml of Standard .Add 0.6ml of Sodium carbonate & 0.6ml 
of phosphotungstic acid. Mix & take OD after 30min at 700mm. 
Concentration of Standard is 0.03 
Volume of test is 0.3 
Calculation: Uric acid in 100ml serum OD of test conc. of STD 
-------------- x ------------------ x 100 = ---- ml /dl 
OD of STD volume of test 
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  Anti-oxidant capacity 
    Uric acid is thought to be a marker of increased oxidative stress. Uric acid 
has a good therapeutic role as an antioxidant, like other reducing substances 
which has antioxidant properties such as ascorbate. Uric acid also acts as a 
peroxidant, most commonly at increased or elevated levels in serum.   
       It is not very clear that whether increased levels of uric acid in diseases 
associated with oxidative stress like stroke, atherosclerosis and 
cerebrovascular accident are a protective response or a primary cause for 
these diseases. 
 So some of the researchers thought that hyper uricemia induces oxidative 
stress which is a cause of metabolic syndrome. At the other side increased 
plasma uric acid levels corresponds with longevity in primates and other 
animals. This may be due to its function as antioxidant                                            
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Mortality and Morbidity     
        In patients with hypertension and hyperuricemia have increased 
morbidity and significant association with each other. Increased serum uric 
acid levels also associated with increased in the mortality patients who are 
all women and aged persons. Because for this increased mortality is 
unknown, but hyperuricemia maybe a marker for comorbid risk factors in 
diseases rather than a causative factor. 
 
URIC ACID AND VARIOUS DISEASES 
      High serum uric acid levels and low serum uric acid levels associated 
with many human illness and disease state. An abnormally increased serum 
uric acid level has been associated with the development of gout, 
hypertension, renal disease and cardiovascular disease in humans.  
         Hypouricemia associated with the development of CNS diseases like 
Alzheimer’s disease, Multiple sclerosis, Parkinson's disease, and optic 
neuritis 
        Alternatively increasing serum uric acid has been used for the treatment 
of neurodegenerative diseases of brain for example multiple sclerosis and for  
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the management of both stroke and spinal cord damage or injury. Use of 
hyperuricemia in management of these disease is due to its neuroprotective 
effects and properties 
 Uric Acid Balance 
      In extra cellular fluid, uric acid which is a weak acid distributed in the 
form of sodium urate. The amount of urate seen in the blood depends on the 
intake of purines through diet, amount of urate excretion and biosynthesis of 
urate. 
      Serum uric acid levels are regulated by a four components renal transport 
system which involves glomerular filtration, glomerular secretion, 
reabsorption and post secretory reabsorption. 
There are many kidney urate transporters system are involved in the 
regulation of serum and plasma urate levels in humans. They include urate 
transporter 1 also called as URAT1, this is also responsible for the 
reabsorption of urate in the kidneys. There are many other   number of 
organic ion transporters (OAT) in urate transport system, such as organic ion 
transporters OAT1 and OAT3 . Also ATP-dependent urate export transporter 
that is MRP4 also involved in the secretion of urate. 
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       Nearly 90% of the filtered urate in human kidneys are reabsorbed, 
because of the involvement URAT 1 in urate reabsorption. URAT1 is 
thought as a very critical in the regulation of plasma urate levels in kidneys. 
 
Hyperuricemia and Hypertension 
               Hyperuricemia has strong association in predicting the 
development of hypertension in the general population, the elevated levels of 
serum uric acid may be due to the decrease in renal blood flow which 
develops in the early stages of hypertension. 
               A reduced blood flow in renal vasculature alters the medullary and 
cortical circulation balance, which then resulting in a decreased secretion of 
urate by the kidneys.  
              Hypertension can also lead to microvascular disease resulting in 
local tissue ischemia .This tissue ischemia leads to an increase in the 
production of uric acid resulting in an increased serum uric acid level. These 
mechanisms in kidney clearly shows that the increase in the plasma levels of 
uric acid may be a consequence of hypertension. 
Hyperuricemia in Cardiovascular Disease 
              Hyperuricemia is a major risk factor for the development of 
cardiovascular diseases like myocardial infarction, and stroke. Elevated 
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serum uric acid levels are also act as an independent risk factor for increased 
cardiovascular mortality.  
              Increased serum uric acid levels associated with increased 
cardiovascular disease, this may be due to its antioxidant property. Increased 
levels of uric acid also contribute to the increased number of cardiovascular 
disease due to its negative effect on the endothelium in the vessels.  
             Levels if Uric acid concentrations sometimes increase due to its 
attempt to block peroxidation of lipids and other related reactions. This also 
clearly shows that increased uric acid levels are a consequence of cardiac 
disease. 
            There is  also  some other evidences  that  shows serum uric acid can  
possibly increase rather than prevent oxygenation of  cholesterol, low 
density lipoprotein  and  Peroxidation of lipids. This leads to an increase in 
the adhesiveness of platelets to the vessels which then results in formation of 
thrombus. This thrombus formation then contribute to the development of 
atherosclerosis and also increases the future development of cardiovascular 
disease. 
              This increased serum uric acid levels also stimulates the release of 
free radicals, which are thought to be involved in the expression of adhesion 
molecules both by the inflammatory cells and inflammatory cell activation. 
Adherence of this free radicles to the damaged endothelium causes one of 
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the component of Virchow’s triad. This later results injury to the endothelial 
cells and   increasing the risk of development of cardiovascular disease. 
 
Uric Acid and Neuroprotection 
             Uric acid has up to 60 % of scavenging the free radicals in the 
human blood due to its natural anti-oxidant property. Uric acid can scavenge 
various free radicals like superoxide, the hydroxyl radical, and singlet 
oxygen. Uric acid helps in the removal of superoxide by acting against the 
destruction of superoxide dismutase which is an enzyme. 
            Superoxidase dismutase enzyme is very important for removing the 
superoxide from the cells of the humans. Removal of superoxide by this 
enzyme helps in prevention of its reaction with nitric oxide by blocking the 
production of peroxynitrite. 
             Uric acid is very effective in preventing peroxynitrite, which are part 
of proteins in the cell.  By this way they prevent the inactivation of cellular 
enzymes and the cytoskeleton modification. 
             Uric acid acts in astroglia which present in the central nervous 
system.in this cells uric acid up regulates the protein levels of EAAT-1 
.EAAT-1, which is a glutamate transporter protects the neurons in the spinal 
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cord from toxicity induced by glutamate. Uric acid protects the cells through 
a direct, astroglia mediated mechanism. 
 Hyperuricemia in gout 
              Gout is a type of crystal deposition disease. It is the most common 
form of arthritis involving joints due to errors in metabolism of purine. 
Monosodium urate crystals which are formed due to the error in metabolism 
are deposited in the joints and tissues around the joints 
             Gout are known in very ancient period and one of the oldest known 
disease. Gout clinically cause inflammation which are painful around the 
joints of lower or upper extremities. It sometimes affects more than one 
joints. Most commonly it affects the lower extremity. Nodules formed by 
gout which are deposited in soft tissues are called as tophi.  
             Acute attack of gout causes painful joints which lasts for a short 
period and causes the patient a temporary disablement. This acute attacks of 
gout later predispose to further attacks of gout in future.  
            The main cause for development of gout is increased levels of uric 
acid in blood which are metabolic by products of purines. This increased 
levels of uric acid also called as hyperuricemia. This increased levels of uric 
acid is calculated to affect approximately 20 % of population. 
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                   MATERIALS AND METHODS 
 
 
STUDY DESIGN 
 
       This is a prospective study conducted on a sample south Indian 
population admitted in department of medicine and department of 
gastroenterology during the period of 2013 and 2014. The study includes a 
standardized questionnaire and examination based on this patients were 
included in this study. A total number of 100 patients who are all diagnosed 
to have fatty liver and cirrhosis are included in this study. Patients with prior 
history of alcoholic liver disease, chronic kidney disease, arthritis, 
cardiovascular disease and diabetes mellitus, hypothyroidism are excluded. 
The total number of patients included in this study was 100 out of which 75 
are males and 25 are females 
 
INCLUSION CRITERIA  
   Age of the patients between 30 years to 60 years without the prior history 
of alcoholism, diabetes mellitus, kidney disease, hypothyroidism, drug intake 
and cardiac disease 
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EXCLUSION CRITERIA 
1. Age less than 30 years and more than 60 years 
2. Gout 
3. Chronic alcoholics 
4. Known case of alcoholic liver disease 
5. Chronic kidney disease 
6. Hypothyroidism 
7. Drug intake 
8. Diabetes mellitus  
9. Cardiac disease 
10. Obesity 
 
METHODS 
     A detailed history was elicited from the patient regarding their present 
complaints, associated symptoms, alcohol intake, smoking, previous history 
of hypertension, diabetes mellitus, arthritis, hypothyroidism, any cardiac 
illnesses and chronic drug intake. 
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           On admission routine blood investigations like blood sugar, urea, 
serum creatinine, liver function test, thyroid profile, lipid profile, ultra 
sonogram and serum uric acid levels were estimated. Waist circumference in 
males and females measured. Diabetes was defined as fasting blood sugar 
>126 mg % and post prandial blood sugar >200 mgs%. Body mass index 
was calculated as weight in kg/ height in m2. Serum uric acid levels also sent 
for analysis on the day of admission. The reagent for serum uric acid is 
uricase and for blood glucose trider method is used. 
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                             STATISTICAL ANALYSIS 
 
             Data analysis was done and the subjects were divided in to two 
groups.  One group with ultrasonagram findings of fatty liver and another 
group with the findings of cirrhosis of liver.  Serum uric acid levels in both 
the groups are analysed with age and sex  
           Using the SPSS 20 and sigma stat 3.5 version software, means, 
standard deviations, range, frequencies, percentages, chi-square and ‘p’ 
values were calculated. One way ANONA and student’s t test for data and 
chi square test for consolidation of tables used. A ‘p’ value of < 0.05 was 
taken as significant relationship.  
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                          RESULTS AND OBSERVATIONS 
 
The study population has 100 patient in the age group of 30 years to 60 
years. The mean age of total population is 46.81. The mean age for male is 
47.52. The mean age for female is 44.68 
 
 
 
AGE DISTRIBUTION IN STUDY POPULATION 
AGE MALE FEMALE Total   
< 30 1 4 5   
31 TO 40 18 6 24   
41 TO 50 28 6 34   
51 TO 60 28 9 37   
TOTAL 75 25 100   
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The mean age of the total population was 46.81 years. The mean age of male 
was 47.52years and the mean age of female was 44.68. The mean age for 
male is higher than female 
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The studied population had 75% of males and 25% of females 
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The studied population showed among the 100 patients 42 persons had 
hyperuricemia in the average of 7 to 9. The mean uric acid level is 6.73 
 
 
 
 
URIC ACID
No of 
Cases
3.1 TO 5.0 24
5.0 TO 7.0 26
7.0 TO 9.0 42
> 9 8
TOTAL 100
URIC ACID
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Mean uric level in the studied population was 6.73. Men had relatively 
higher uric acid levels when compared to women. P value is 0.002 which is 
significant in this study. Mean uric acid level in male was 6.93 and mean 
uric acid in female was 6.11. 
 
 
 
 
 
  
93 
 
 
 URIC DISTRIBUTION IN MALE AND FEMALE 
           
 URIC ACID MALE FEMALE TOTAL   . 
3.1 TO 5.0 16 8 24   
 5.0 TO 7.0 17 9 26   
 7.0 TO 9.0 34 8 42   0.002  Significant 
      
> 9 8 0 8   
 TOTAL 75 25     
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               In this studied population patients in the older age group had higher 
uric acid levels compared to the younger patients. But the P value is o.792 
which showed no significance 
 URIC ACID AND AGE 
             
 URIC ACID < 30 31 TO 40 41 TO 50 > 50   
  3.1 TO 5.0 3 7 8 6   
 5.0 TO 7.0 0 8 9 9   
 7.0 TO 9.0 1 8 16 17   0.792  Not significant 
> 9 1 1 1 5   
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TOTAL 5 24 34 37   
  
 
 
 
In the studied population BMI, hyperuricemia associated with high BMI 
which is significant. P value is 0.009 
Uric acid and BMI 
URIC ACID 22 TO 23 23.1 TO 24 24.1 TO 25 >25 
3.1 TO 5.0 6 13 4 1 
5.0 TO 7.0 2 8 9 7 
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7.0 TO 9.0 0 2 16 24 
> 9 0 0 0 8 
TOTAL 8 23     
 
 0.009  Significant 
 
 
 
In this studied population patient with hyperuricemia associated with 
increased waist circumference which is significant. P value is 0.012 
URIC ACID AND WAIST 
URIC ACID 75 TO 80 81 TO 85 86 TO 90 91 TO 95 96 TO 100 101 TO 110 
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3.1 TO 5.0 11 4 3 4 2 0 
5.0 TO 7.0 3 7 6 6 4 0 
7.0 TO 9.0 1 0 5 5 12 19 
> 9 0 0 1 3 1 3 
TOTAL 100           
    
0.012  Significant 
 
 
In this studied population smoking does not correlated with hyperuricemia 
 
SMOKER 
   URIC ACID No of Cases YES NO 
3.1 TO 5.0 24 4 20 
5.0 TO 7.0 26 9 17 
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7.0 TO 9.0 42 0 42 
> 9 8 0 8 
TOTAL 100     
 
 
In this studied population hyper bilirubinemia associated with hyperuricemia 
which is significant. P value is <0.001 
    BILIRUBIN   
URIC ACID No of Cases MEAN Std Dev 
3.1 TO 5.0 24 2.492 0.836 
5.0 TO 7.0 26 2.788 1.493 
7.0 TO 9.0 42 5.11 1.859 
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> 9 8 4.425 2.241 
TOTAL 100     
  
< 0.001  Significant 
 
 
 
In this studied population increased SGOT levels associated with 
hyperuricemia which is significant. P value is <0.001 
    SGOT   
URIC ACID No of Cases MEAN Std Dev 
3.1 TO 5.0 24 50.25 46.832 
5.0 TO 7.0 26 58.462 23.261 
 
  
100 
 
7.0 TO 9.0 42 103.905 70.162 
> 9 8 141.5 158.98 
TOTAL 100     
 
< 0.001  Significant 
 
 
 
 
 
In this studied population increased SGPT levels associated with 
hyperuricemia which is significant. P value is <0.001 
    SGPT   
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URIC ACID No of Cases MEAN Std Dev 
3.1 TO 5.0 24 54.417 19.662 
5.0 TO 7.0 26 59.846 21.581 
7.0 TO 9.0 42 106.214 51.984 
> 9 8 89.875 60.829 
TOTAL 100     
 
< 0.001  Significant 
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In this studied population increased alkaline phosphatase levels associated 
with hyperuricemia which is significant. P value is <0.001 
 
 
 
    ALP   
URIC ACID No of Cases MEAN Std Dev 
3.1 TO 5.0 24 104.958 36.281 
5.0 TO 7.0 26 111.231 40.522 
7.0 TO 9.0 42 158.167 42.038 
> 9 8 126.625 84.356 
TOTAL 100     
 
< 0.001  Significant 
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In this studied group blood sugar values not correlated with uric acid levels. 
P value not   significant. P value is 0.148 
 
    Sugar   
URIC ACID No of Cases MEAN Std Dev 
3.1 TO 5.0 24 93.625 11.776 
5.0 TO 7.0 26 102.038 22.49 
7.0 TO 9.0 42 99.952 8.859 
> 9 8 92.75 20.041 
TOTAL 100     
  
0.148  Not significant 
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In this studied population blood urea levels not correlated well with the uric 
acid levels. P value not significant (P value 0.094) 
    Urea   
URIC ACID No of Cases MEAN Std Dev 
3.1 TO 5.0 24 29.458 7.095 
5.0 TO 7.0 26 27.423 7.829 
7.0 TO 9.0 42 31.024 5.493 
> 9 8 32.625 3.926 
TOTAL 100     
 
0.094   Not significant 
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 In this studied group serum creatinine level not correlated with serum uric 
acid levels. P value 0.093 not significant 
    Creatinine   
URIC ACID No of Cases MEAN Std Dev 
3.1 TO 5.0 24 0.892 0.301 
5.0 TO 7.0 26 0.912 0.297 
7.0 TO 9.0 42 0.769 0.199 
> 9 8 0.937 0.385 
TOTAL 100     
 
0.093  Not significant 
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In this study group hypercholesterolemia associated well with the increased 
uric acid levels. P value is significant. P value is <0.001 
 
    Cholesterol   
URIC ACID No of Cases MEAN Std Dev 
3.1 TO 5.0 24 132.458 35.545 
5.0 TO 7.0 26 161.385 37.709 
7.0 TO 9.0 42 201.786 22.118 
> 9 8 221.125 39.226 
TOTAL 100     
 
< 0.001  Significant 
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In this study increased levels of triglycerides associated with increased 
serum levels of uric acid. P value is significant (P <0.001) 
    Triglycerides   
URIC ACID No of Cases MEAN Std Dev 
3.1 TO 5.0 24 131.5 27.707 
5.0 TO 7.0 26 147.692 31.347 
7.0 TO 9.0 42 205.619 46.098 
> 9 8 199.125 59.686 
TOTAL 100     
  
< 0.001  Significant 
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In this study population hyperuricemia associated with increased number of 
cases of cirrhosis. But the p value is 0.696 which is not significant 
URIC ACID cirrhosis 
3.1 TO 5.0 6 
5.0 TO 7.0 12 
7.0 TO 9.0 23 
> 9 4 
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In this study increased number of patients seen both in lower and higher 
levels of uric acid. This has no clinical significance. 
 
URIC ACID fatty liver 
  
3.1 TO 5.0 18 
5.0 TO 7.0 14 
7.0 TO 9.0 19 
> 9 4 
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ASSOCIATION OF CIRRHOSIS AND FATTY LIVER WITH URIC 
ACID IN MEN 
 
In this study group male patients with increased levels of uric acid associated 
well with cirrhosis and fatty liver. This is significant 
 
 
 
 
 
 
2
8
24
13
10
18
0
5
10
15
20
25
30
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ASSOCIATION OF CIRRHOSIS AND FATTY LIVER WITH URIC 
ACID IN WOMEN 
 
This study in female population had strong association with increased uric 
acid levels and cirrhosis and fatty liver. This is significant value 
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                                  DISCUSSION 
 
URIC ACID AND GENDER 
           Out of the 100 patients studied, the mean uric acid in the total 
population is 6.73, of which men had higher mean uric acid level when 
compared to female. But there was no statistical significance between these 
two groups. 
URIC ACID AND AGE 
        The mean age in the study group was 46.81years. The mean age for 
male are 47.52 years and the mean age for the female are 44.68 years. Men 
had higher mean age compared to women. 
       The mean age of onset of liver disease is higher in male compared to 
female. In our study it was observed that uric acid levels increase with age in 
male. But exact age group could not be identified. 
 
RISK FACTORS AND URIC ACID 
       In this study hyperbilirubinemia, hypercholesterolemia, BMI, waist 
circumference significantly associated with hyperuricemia. 
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          Our study did not showed any positive correlation of smoking with 
hyperuricemia. Dharma et al has showed similar results. 
         Body mass index showed statistically significant association with uric 
acid levels. It was observed that subjects with BMI of 25 associated will with 
hyperuricemia.  
              South Asian people are more prone for development of 
cardiovascular disease even in the presence of lower BMI. This indicates that 
people with higher BMI have still more increase in the cardiovascular risk. 
Many studies done in this association of BMI with uric acid showed proven 
results. 
          According to our observation uric acid is useful in identifying 
cardiovascular risk in people with high BMI. In our study we have not 
included any risk factors. So hyperuricemia in high BMI is one the risk 
factors for the development of metabolic syndrome in future. 
        In our study we observed that nonalcoholic patients with ultrasonagram 
findings of cirrhosis had increased uric acid levels in both the sex. This 
clearly shows the association of hyperuricemia in cirrhosis. It indicates that 
in advanced liver diseases due to the oxidative stress and endothelial 
dysfunction serum uric acid level also increases. 
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         In our study we also observed that people with fatty liver also had 
associated  high uric acid levels. This shows that people with fatty liver and 
hyperuricemia in future may progress to the advanced liver disease, cirrhosis 
which is correlated well with the laboratory values of liver function tests. 
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                                       CONCLUSION 
 
             Uric acid is an old molecule with many new applications and it has 
also been studied in various metabolic diseases, cardiovascular diseases and 
chronic kidney disease. In this study it has been found that uric acid has a 
significant correlation with BMI, waist circumference and 
hypercholesterolemia. 
           Hyperuricemia is also associated with both alcoholic and 
nonalcoholic liver diseases due to increased oxidative stress and 
inflammatory actions. This  study also concluded that hyperuricemia is 
associated with increased number of cases both with cirrhosis and fatty liver. 
This clearly indicates that hyperuricemia in fatty liver patients, who are 
nonalcoholic have considerable risk for future progression to cirrhosis of 
liver. 
       Because of its association with BMI, waist circumference and 
hypercholesterolemia, hyperuricemia may be considered as one the risk 
factor for metabolic syndrome. 
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LIMITATIONS OF THE STUDY 
 
       In this study progression of the disease in both male and female age 
group could not be identified properly. We are also not able to correlate the 
association of other investigations like  renal function tests. Ultrasonagram 
findings not well correlated with age and sex group. Further confirmation of 
the study needs liver biopsy. 
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ANNEXURES 
 
PROFORMA 
ABBREVATIONS 
MASTER CHART 
     
 
 
 
 
 
 
 
ASSOCIATION OF HIGH URIC ACID LEVELS IN 
CHRONIC LIVER DISEASE 
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      PROFORMA 
 
                                                                                         Medical 
unit 
 
Case No: 
 
Name of the patient: 
 
 
Sex:         Age                     Ht            Wt              BMI                   Waist 
 
History of present illness: 
 
 
 
Past History: 
 
Diabetes mellitus   
Hypertension          
Ischemic Heart disease 
Lung disease 
Thyroid disease 
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Renal disease 
Liver disease 
 
Drug History: 
Beta-blockers 
Diuretics 
Lipid lowering agents: 
Steroids 
 
 
Personal History: 
Diet 
Smoking 
Alcohol 
 
Family History: 
CVD 
HTN 
Dyslipidemia  
Diabetes 
 
GENERAL PHYSICAL EXAMINATION: 
Built 
Pallor 
Icterus 
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Clubbing 
Oedema 
Cyanosis 
 
 
VITALS: 
BP                PR                RR 
 
 
SYSTEMIC EXAMINATION: 
1. Respiratory System 
 
2. Cardiovascular System 
 
3. Abdominal System 
 
 
 
      4.  Nervous System 
 
 
INVESTIGATION:  
 
1. LFT  
 
 
  
124 
 
2. RFT 
 
3. Lipid profile 
 
4 Serum Uric acid 
 
 5. Blood sugar 
 
6. USG Abdomen 
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ABBREVATIONS 
NAFLD – Nonalcoholic liver disease 
NASH – Nonalcoholic steato hepatitis 
BMI – Body mass index 
CLD – Chronic liver disease 
UA – Uric acid 
HCC – Hepato cellular carcinoma 
ALD – Alcoholic liver disease 
CHREBP –  Carbohydrate, responsive element binding protein 
VLDL – Very low density lipoproteins 
MTP – Microsomal triglyceride transfer protein 
NEFA – Non essential fatty acid 
TGL – Triglycerides 
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HDL – High density lipoproteins 
LDL – Low density lipoproteins 
GGT- Gama glutamyl transferase 
ALT – Alanine transaminase 
AST – Aspartate transaminase 
  
 
 
MASTER CHART: 
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